Clinical Trial Search Results
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
You are being asked to take part in this research study because your tumor results from the NCI-COG Pediatric MATCH screening protocol make you a candidate to receive the study drug called BVD-523FB (ulixertinib) that we are te ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROSI Genomic Alterations
You are being asked to participate in this study because you have a relapsed or refractory tumor without a proven treatment strategy for cure. The main goal of this study is to test any good and bad effects of the ensartinib on ...
NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
The overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.
NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
This is a Phase 2 study of a drug called LOXO-292. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. LOXO-292 is experimental because it has not been proven t ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
This is a Phase 2 study of a drug called LY3023414. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
The main goal is to test any good and bad effects of the study drug olaparib on your tumor. A second goal of the study is to evaluate side effects that might be caused by olaparib and to learn more about the pharmacology (how y ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
The main goal of this study is to test any good and bad effects of the palbociclib on your tumor. A second goal of the study is to evaluate side effects that might be caused by palbociclib.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations
The main goal is to test any good and bad effects of the study drug selumetinib (AZD6244 hydrogen sulfate) on your tumor. A second goal of the study is to evaluate side effects that might be caused by selumetinib (AZD6244 hydro ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evalua ...